This alteration (30% reduction in hepatic and intestinal CYP3A4 expression) has been investigated in a PBPK study demonstrating a better prediction of exposure to sensitive CYP3A4 substrates (namely, midazolam and simvastatin) in patients with cancer [16]. This evidence concerns the gene CYP3A4 and cancer.